- Home
- ATAT vs APGE Comparison
ATAT vs APGE Comparison
Compare ATAT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- APGE
- Stock Information
- Founded
- ATAT 2013
- APGE 2022
- Country
- ATAT China
- APGE United States
- Employees
- ATAT N/A
- APGE N/A
- Industry
- ATAT Hotels/Resorts
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAT Consumer Discretionary
- APGE Health Care
- Exchange
- ATAT Nasdaq
- APGE Nasdaq
- Market Cap
- ATAT 2.9B
- APGE 3.3B
- IPO Year
- ATAT 2022
- APGE 2023
- Fundamental
- Price
- ATAT $26.03
- APGE $56.23
- Analyst Decision
- ATAT Strong Buy
- APGE Strong Buy
- Analyst Count
- ATAT 2
- APGE 4
- Target Price
- ATAT $23.69
- APGE $72.25
- AVG Volume (30 Days)
- ATAT 1.7M
- APGE 454.3K
- Earning Date
- ATAT 11-14-2024
- APGE 11-11-2024
- Dividend Yield
- ATAT 1.73%
- APGE N/A
- EPS Growth
- ATAT 250.03
- APGE N/A
- EPS
- ATAT 1.04
- APGE N/A
- Revenue
- ATAT $834,559,715.00
- APGE N/A
- Revenue This Year
- ATAT $51.03
- APGE N/A
- Revenue Next Year
- ATAT $24.14
- APGE N/A
- P/E Ratio
- ATAT $26.02
- APGE N/A
- Revenue Growth
- ATAT 91.74
- APGE N/A
- 52 Week Low
- ATAT $15.06
- APGE $14.19
- 52 Week High
- ATAT $29.15
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- ATAT 57.53
- APGE 54.70
- Support Level
- ATAT $26.29
- APGE $52.82
- Resistance Level
- ATAT $27.72
- APGE $57.10
- Average True Range (ATR)
- ATAT 1.10
- APGE 2.60
- MACD
- ATAT -0.33
- APGE -0.35
- Stochastic Oscillator
- ATAT 17.89
- APGE 47.66
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.